Functional heterogeneity of circulating T regulatory cell subsets in breast cancer patients.

BACKGROUND

Regulatory T cells (Tregs) play a major role in tumor escape from immunosurveillance by suppressing effector cells. The number of Tregs is increased in tumor sites and peripheral blood of breast cancer patients. However, the data regarding phenotypic and functional heterogeneity of Treg subpopulations in breast cancer are limited. The present study aimed to investigate the number and suppressive potential of Tregs that possess natural naïve-(N nTregs), effector/memory-like (EM nTregs), and Tr1-like phenotypes in breast cancer patients and healthy women.

METHODS

The study included 10 HW and 17 primary breast cancer patients. Numbers of CD4CD25FoxP3CD45RA N nTregs, CD4CD25FoxP3CD45RA EM nTregs, and CD4IL-4IL-10 Tr1 subsets and the expression of CTLA-4, CD39, GITR, LAP, and IL-35 by these Treg subsets were measured in freshly obtained peripheral blood by flow cytometry.

RESULTS

Herein, we demonstrate that the percentages of N nTregs, EM nTregs, CD25 and FoxP3 Tr1 cells are elevated in the peripheral blood of breast cancer patients, but do not correlate with cancer stages. Nevertheless, the frequency of CD25 Tr1 cells was associated with nodal involvement, while the number of EM nTregs correlated with clinical outcome. The expression of CTLA-4 and IL-35 by all assessed Treg subsets was increased throughout all tumor stages (I-III).

CONCLUSIONS

Collectively, the current study shows phenotypic alterations in suppressive receptors of Treg subsets, suggesting that breast cancer patients have increased activity of N nTregs, EM nTregs and Tr1 cells; and EM nTregs and CD25 Tr1 cells represent prospective markers for assessing disease prognosis.